Clinical trials: Stage I Skin Cancer
Breast Cancer, Cancer Survivor
Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors
RATIONALE: Telephone sessions and survivorship booklets may increase knowledge about the psychological and physical impact of breast cancer and increase awareness of available resources.
- Conditions
- Breast Cancer, Cancer Survivor, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00932997
- Testing
- telephone-based intervention, counseling intervention, educational intervention
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- City of Hope Medical Center
Melanoma, Advanced Melanoma
Study of Temzolomide and Gleevec in Advanced Melanoma
This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients…
- Trial name
- NCT00667953
- Testing
- Gleevec, Temodar
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-melanomatous Skin Cancer
Celecoxib in Preventing Skin Cancer
RATIONALE: Celecoxib may be effective in preventing skin cancer by decreasing redness caused by exposure to ultraviolet light and changing potential skin cancer biomarkers.
- Trial name
- NCT00025051
- Testing
- celecoxib, anti-cytokine therapy, antiangiogenesis therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
- Trial name
- THERAVAC (NCT01331915)
- Testing
- Theravac
- Where
- Belgium
- Volunteers
- 23 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04294225
- Testing
- Anastrozole, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mayo Clinic
Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This clinical trial is studying the side effects of partial breast radiation therapy and how well it works in treating women undergoing breast…
- Conditions
- Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00599989
- Testing
- adjuvant therapy, conventional surgery, 3-dimensional conformal radiation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer, Breast Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01623349
- Testing
- BKM120 and Olaparib, BYL719 and Olaparib
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
This Phase 1 trial will investigate the safety of a modified stem cell transplant procedure for treating advanced breast cancer.
- Trial name
- NCT00079625
- Testing
- Th2/Tc2 Cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
This phase I/Ib trial tests the safety, side effects, best dose, and effectiveness of ASTX660 (tolinapant) in combination with eribulin mesylate (eribulin) in treating patients with triple negative breast cancer that cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Negative Breast Carcinoma
- Trial name
- NCT06590558
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
This study tests four different methods of educating patients about follow-up care (NCI facing forward, brochure, EXCELS website alone, EXCELS health coaching alone and EXCELS website \& health coaching combination) after cancer…
- Conditions
- Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer
- Trial name
- NCT03233555
- Testing
- Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 535 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00674414
- Testing
- trastuzumab, everolimus, therapeutic conventional surgery
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- UNICANCER
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00004925
- Testing
- trastuzumab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Radiation Dermatitis, Breast Cancer
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity.
- Trial name
- NCT05269160
- Testing
- Dermaprazole 1%, Dermaprazole 2%
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Breast Cancer
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer.
- Trial name
- NCT01349322
- Testing
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost
- Where
- 415 sites in United States, Canada and 6 more
- Volunteers
- 2,354 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer, Drug-induced Nausea and Vomiting
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
RATIONALE: Acupressure may help to reduce or prevent nausea in patients who are undergoing chemotherapy. It is not yet known whether acupressure plus standard care for nausea is more effective than standard care alone for nausea…
- Trial name
- NCT00046865
- Testing
- acupressure therapy, management of therapy complications, nausea and vomiting therapy
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
HER2/Neu Positive, Recurrent Breast Carcinoma
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
This phase I trial studies the side effects and the best dose of Z-endoxifen hydrochloride in treating patients with estrogen receptor-positive (ER+) breast cancer that has spread to other places in the body (metastatic) or has…
- Conditions
- HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01327781
- Testing
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This is an open-label, dose-finding, safety, pharmacokinetics (PK), and evidence-of-activity study of GDC-0927 in postmenopausal women with locally advanced or metastatic Estrogen Receptor Positive (ER+) Human Epidermal Growth…
- Trial name
- NCT02316509
- Testing
- GDC-0927
- Where
- 13 sites in United States, Spain
- Volunteers
- 43 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.